Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > ATE

<< Previous

Bullboard Posts

Next >>

Comment by GameChangerBeton Jul 15, 2021 12:55pm

187 Views

Post# 33552718

RE:RE:ATE

Absolutely agree.
And i'm glad there are some rational individuals here who understand what my message was.

MikeStock wrote: Building on your post GCB, I spoke to Dan last week and left the call feeling comfortable with my investment. Yes, I don't like the SP, but don't think that ATE management likes it either. They are fully aware and it is regularly discussed at the board level.

My main piece of feedback to him was that their news releases leave too much to the imagination about what is meant and often don't include an explanation. Perfect example, P3 is now 2022. But why? It's a 6 week delay and it likely has a good reason but they typically don't explain that. He said he would take that feedback back to his comms team.

I asked about NAZ, 352 and P3 timing. He said he would provide an update on that in his next shareholder letter and he has comitted to doing them twice per year. It is scheduled for late July or early Aug. I'm not quite sure.

They have a team of advisors providing guidance and recommendations on all strategic aspects of the business. This discussion board makes it sound like Dan is drunk and blindly making reckless decisions. He's aware of the comments on here, but if/when a deal is done, he's everyone hero and we all know that to be true.

I don't like the SP any more than any of you and I'm currently sitting with a well over 6 figure loss at the moment. There's value here and bringing a new drug to market is hard. This is dollars to us, but it is their legacy so they want this to succeed. Cheers and GLTA.

GameChangerBet wrote: Up $.04+. Maybe my Reddit post worked!

In all seriousness, I think there needs to be some action by shareholders.
If you have concerns, stop posting it repeatedly on stockhouse and making stockhouse rich from increased ad revenue.
Contact Dan, the person who seems to be the major source of your concerns, directly.
His information is public. Email him, call him.
It may not make an immediate impact, but at least if enough voices singing the same song are heard, then perhaps the message will get accross, if the concerns are warranted.

Wasn't kidding about Reddit, get on there if you have to, post the facts.
There are millions of members there, if it cathces on then it may actually produce some recognition and ignite some movement.
Virtually bankrupt companies being talked about are getting majorly bid up resulting in massive stock spikes.
We actually have a legitimate product with Billions of dollars of a target market.

Make some calls, write some emails.
Annual general meeting is coming up, vote againts whoever you think should not be there, it may not work but at least it will send the message of what the sentiment of shareholders are.

It's your money at stake, start taking action within your capabilities.